Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 02, 2024 07:26 ET
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...
Resolutions from the Annual General Meeting of Novo Nordisk A/S
March 21, 2024 10:59 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “We are very...
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
March 18, 2024 07:28 ET
|
Arch Biopartners
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients...
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
March 15, 2024 07:05 ET
|
Arch Biopartners
TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of...
CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations
February 07, 2024 09:13 ET
|
Wohl & Fruchter LLP
MONSEY, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Catalent, Inc. (NYSE: CTLT) (“Catalent”) has violated federal securities laws based...
Airfinity launches world’s first obesity data and analytics platform
January 24, 2024 04:57 ET
|
Airfinity
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market. ...
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
|
Novo Nordisk A/S
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
January 03, 2024 07:33 ET
|
Arch Biopartners
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the...
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
December 13, 2023 07:25 ET
|
Arch Biopartners
TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to...
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
November 11, 2023 08:31 ET
|
Novo Nordisk A/S
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...